The potent preclinical activity formed the rationale for a phase 1 trial in which lorvotuzumab mertansine was evaluated as a single agent in 37 relapsed/refractory patients (>3 prior treatment lines in 78% of patients) with CD56-positive MM (42). Here, NCAM1 is linked to Miyoshi myopathy.